QurAlis Early Access Policy

Patients with serious or life-threatening diseases or conditions sometimes seek medical products that are not yet approved or available in their country. This is known as early access, managed access, or expanded access. Early access programs are a means by which investigational therapies are made available, in certain circumstances, to treat patients with serious diseases who are unable to participate in an ongoing clinical trial or whose treatment options are otherwise limited.

Before a new product can be placed on the market, it must undergo well-controlled clinical trials to demonstrate that it is safe and effective, and its potential benefit to patients outweighs the possible risks. A clinical trial is a research program conducted with volunteer participants to evaluate an investigational new drug or medicine in which comprehensive safety and efficacy data are compiled. Clinical trial results and related product information are then submitted to the relevant health authorities for review. Clinical trials result in the generation of evidence and information that may lead to the approval of an investigational new drug or medicine, which can make it more widely available to patients.

Currently, QurAlis does not have investigational medicines available through an expanded access program. QurAlis believes that participating in clinical trials is the best way for patients to access investigational medicines. QurAlis will strive to design trials that are inclusive of as many patients as possible, but we recognize that not every patient will be eligible for these trials.

For those patients who have completed a QurAlis clinical trial, it is our plan, when supported by the scientific data, to provide access to the investigational medicine until it is approved and available locally.

QurAlis will continue to assess early access as our clinical programs progress and may reconsider making one or more of its investigational medicines available through an Expanded Access Program in the future.